엔지켐생명과학 Stock: price and insider trades · South Korea
No insider purchase over the last 90 days. The latest, by 김진원, was filed 27 Jul 2026.
Who traded when
BuySaleSince the insiders bought
- +0.0%Entry ₩990 · Close 30 Oct 2026 ₩990
- +0.0%Entry ₩990 · Close 30 Oct 2026 ₩990
- +0.0%Entry ₩990 · Close 30 Oct 2026 ₩990
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- Other0DART
- 55,000 sharesShareKRXDART:20260727000286Canonical exit: 25 Oct 2026 (T+90)
- Other0DART
- Other0DART
- Other0DART
- KRXDART:20260707000016
- ●Executives0DART
- ●Executives0DART
- 7,200 sharesKRXDART:20260619000629
- 5,035,780 sharesKRXDART:20260605000186Canonical exit: 3 Sept 2026 (T+90)
- 5,065,345 sharesKRXDART:20260605000189Canonical exit: 3 Sept 2026 (T+90)
- 5,065,345 sharesKRXDART:20260601001955Canonical exit: 30 Aug 2026 (T+90)
- 5,035,780 sharesKRXDART:20260528000755Canonical exit: 24 Aug 2026 (T+90)
- 1,105,852 shares1.25% mcap100.0% of flowKRXDART:20260508001022Canonical exit: 6 Aug 2026 (T+90)
- 4,857,465 shares5.47% mcap100.0% of flowKRXDART:20260507000649Canonical exit: 2 Aug 2026 (T+90)
- 0KRXDART:20260420000485
- 7,200 sharesShareKRXDART:20260407003652Canonical exit: 29 Jun 2026 (T+90)
- 7,200 shares0.0079% mcap100.0% of flowKRXDART:20260407003461Canonical exit: 29 Jun 2026 (T+90)
- 8,688,026 shares9.60% mcap100.0% of flowKRXDART:20260406004196Canonical exit: 29 Jun 2026 (T+90)
- 0KRXDART:20260318000393
- 0KRXDART:20260316000999
- 0KRXDART:20260311004127
- ●Executives0DART
- 6,625,447 sharesKRXDART:20260227008612Canonical exit: 21 May 2026 (T+90)
25 of 123 declarations
About 엔지켐생명과학
윤영배, filed as 부사장, signs 54 purchases across 55 filings at 엔지켐생명과학, including the largest, EUR 4,937,058, on March 31, 2026. A purchase by 이수민 follows with EUR 2,813,201 on May 4, 2026, then EUR 640,454 for 브리짓라이프사이언스 on May 8, 2026. Six purchases carry an amount, EUR 8,429,029 in all with a median of EUR 336,225.
This record of 118 filings, published from March 16, 2021 to July 27, 2026, holds a single sale against 66 purchases, and 51 filings of another kind. 브리짓라이프사이언스 (대량보유자) has 42, 4 of them purchases; 남윤희 (대량보유자) 5, 4 of them purchases; the company 엔지켐생명과학 12. From May 4 to June 1, 2026, 3 filers bought. Across the full history, 4 purchase filings are classed as clustered.
Read moreShow less
The South Korean health care company is valued at KRW 83.8 billion; insiders hold 22.2% of the capital. 2022 holds 45 filings, 2023 holds 31, 2026 holds 20, 2024 holds 15, 2021 holds 4 and 2025 holds 3. For 50 purchases the stored 90-day median is minus 16.4%, with 20% positive; a measured past, not a forecast.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
